-
公开(公告)号：WO2016179684A1
公开(公告)日：2016-11-17
申请号：PCT/CA2016/000136
申请日：2016-05-11
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： ZHANG, Li , ACHITA, Paulina , LEE, Jong
IPC: A61K35/17 , A61P35/00 , C12N5/0783
CPC classification number: A61K35/17 , A61P35/00 , C12N5/0637 , C12N2501/51 , C12N2501/515 , C12N2501/999
Abstract: There is provided herein a method for expanding human CD4-CD8- regulatory T cells (DN Tregs) from a population of cells comprising DN Tregs, comprising: culturing the population of cells with artificial antigen presenting cells (APCs), preferably the DN Tregs are αβ-TCR-CD56- or alternatively γδ-TCR+.
Abstract translation: 本文提供了从包含DN Treg的细胞群扩增人CD4-CD8调节性T细胞（DN Treg）的方法，其包括：用人造抗原呈递细胞（APC）培养细胞群，优选DN Treg是 αβ-TCR-CD56-或者γδ-TCR +。
-
公开(公告)号：WO2007056854A1
公开(公告)日：2007-05-24
申请号：PCT/CA2006/001870
申请日：2006-11-20
Applicant: UNIVERSITY HEALTH NETWORK , ZHANG, Li , HAN, Mei , DOKOUHAKI, Pouneh
Inventor： ZHANG, Li , HAN, Mei , DOKOUHAKI, Pouneh
CPC classification number: A61K35/17 , C12N5/0636 , C12N2501/23 , C12N2501/2302 , C12N2501/2304 , C12N2501/515
Abstract: A method of expanding double negative T cells in culture is described. The method comprises (a) providing a starting sample comprising DN T cells or precursors thereof; (b) substantially depleting CD8 + and CD4 + T cells from the starting sample; (c) culturing the sample from step (b) with an immobilized T cell mitogen in a culture medium comprising an agent that can stimulate DN T cell growth; (d) washing the cells obtained in step (c) and resuspending in a culture medium comprising the agent without the T cell mitogen; and (e) washing the cells obtained in step (d) and resuspending in a culture medium comprising the agent and a soluble T cell mitogen. The DN T cells obtained by the method are useful in a variety of applications including the treatment of cancer, infectious diseases, graft versus host disease and autoimmune disease.
Abstract translation: 描述了在培养中扩增双重负T细胞的方法。 该方法包括（a）提供包含DN T细胞或其前体的起始样品; （b）来自起始样品的基本上消耗CD8 +和/或CD4 + T细胞; （c）在包含可刺激DN T细胞生长的试剂的培养基中培养来自步骤（b）的样品与固定的T细胞丝裂原; （d）洗涤步骤（c）中获得的细胞，并重新悬浮在包含没有T细胞丝裂原的试剂的培养基中; 和（e）洗涤步骤（d）中获得的细胞，并重新悬浮于包含该试剂和可溶性T细胞丝裂原的培养基中。 通过该方法获得的DN T细胞可用于各种应用，包括治疗癌症，感染性疾病，移植物抗宿主病和自身免疫性疾病。
-
公开(公告)号：WO2021108926A1
公开(公告)日：2021-06-10
申请号：PCT/CA2020/051682
申请日：2020-12-07
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： ZHANG, Li , LEE, Jong Bok , VASIC, Daniel , KHATRI, Ismat , LY, Dalam , LEUNG, Yuki Sze Long
IPC: C12N5/10 , A61K35/17 , A61P35/00 , C07K14/705 , C07K19/00 , C12N15/62 , C12N15/85 , C12N5/0783
Abstract: The disclosure relates to the development and use of CD4- CD8- double negative T (DNT) cells genetically modified to bind to one or more target antigens to enhance DNT cell anti-cancer activity such as with a chimeric antigen receptor (CAR). Genetically modified DNT cells can be generated ex vivo and expanded from allogeneic healthy donor cells and used as off-the-shelf therapy to overcome allogeneic graft-versus-host disease (GvHD) and/or host-versus-graft rejection in the treatment of cancer.
-
公开(公告)号：WO2021155479A1
公开(公告)日：2021-08-12
申请号：PCT/CA2021/050138
申请日：2021-02-08
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： ZHANG, Li , LEE, Jong Bok , SCHIMMER, Aaron David
IPC: C12N5/0783 , A61K31/437 , A61K35/17 , A61P35/00 , A61P35/02 , C07D471/04
Abstract: Methods of treating T cells with Venetoclax to increase T cell-mediated cytotoxicity and/or T cell mediated anti-tumor activity are described. Also described are populations of enhanced T cells as well as associated methods and uses for the treatment of cancer.
-
公开(公告)号：WO2020124248A1
公开(公告)日：2020-06-25
申请号：PCT/CA2019/051866
申请日：2019-12-19
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： ZHANG, Li , LEE, Jong Bok , KANG, Hyeonjeong
IPC: C12N5/0783 , A01N1/02 , A61K35/17 , A61P35/00
Abstract: Described are methods for the production and use of cryopreservable double negative T cells (DNTs) for the treatment of cancer as an off-the-shelf cellular therapy. A sample population of DNTs is expanded using DNTs from one or more donors. The expanded population of DNTs from different donors does not exhibit alloreactivity against allogenic cells in the expanded population. The expanded populations of DNTs can be long-term stored as cryopreserved products.
-
Patent Agency Ranking
公开(公告)号：WO2016023134A1
公开(公告)日：2016-02-18
申请号：PCT/CA2015/050780
申请日：2015-08-17
Applicant: UNIVERSITY HEALTH NETWORK
Inventor： ZHANG, Li , LEE, Jong Bok , CHEN, Branson
CPC classification number: A61K39/0011 , A61K31/7068 , A61K35/17 , A61K2039/5158
Abstract: Methods for the treatment of cancer using double negative (DN) T cells are described. The DNTs may be used for the treatment of chemotherapy- resistant cancers such as recurring or relapsing acute myeloid leukemia (AML). The use of allogenic DNTs, such as those derived from healthy donors, that do not exhibit toxicity towards normal host tissues and the complications associated with graft-versus-host-disease, is also described.
Abstract translation: 描述了使用双重阴性（DN）T细胞治疗癌症的方法。 DNT可用于治疗化疗耐药性癌症，例如复发性或复发性急性骨髓性白血病（AML）。 还描述了使用不对正常宿主组织显示毒性的同种异体DNT（例如来自健康供体的那些），以及与移植物抗宿主病相关的并发症。
-
公开(公告)号：WO2009103157A1
公开(公告)日：2009-08-27
申请号：PCT/CA2009/000197
申请日：2009-02-20
Applicant: UNIVERSITY HEALTH NETWORK , ZHANG, Li , KIM, Edward , JOE, Betty
Inventor： ZHANG, Li , KIM, Edward , JOE, Betty
IPC: C07K16/28 , A61K35/14 , A61K39/395 , A61P35/00 , A61P35/02 , A61P37/06 , C07K16/18 , C12N15/13 , C12N5/00 , G01N33/567 , G01N33/574 , C07K14/705
CPC classification number: C07K16/28 , A61K35/17 , C07K2317/56 , C07K2317/565 , C12N5/0637 , C12N5/0638 , G01N33/56972 , G01N2333/705
Abstract: The present application provides a novel antibody that is specific for MFAP4. The application also provides methods and uses of MFAP4 as a marker for regulatory cells and/or anti-cancer cells. Further, the application provides methods and uses of MFAP4 binding agents for selection and activation of regulatory cells and/or anti-cancer cells.
Abstract translation: 本申请提供了特异于MFAP4的新型抗体。 该应用还提供了MFAP4作为调节细胞和/或抗癌细胞的标记物的方法和用途。 此外，本申请提供了MFAP4结合剂用于选择和激活调节细胞和/或抗癌细胞的方法和用途。
-
公开(公告)号：EP4069831A1
公开(公告)日：2022-10-12
申请号：EP20896982.4
申请日：2020-12-07
Applicant: University Health Network
Inventor： ZHANG, Li , LEE, Jong Bok , VASIC, Daniel , KHATRI, Ismat , LY, Dalam , LEUNG, Yuki Sze Long
IPC: C12N5/10 , A61K35/17 , A61P35/00 , C07K14/705 , C07K19/00 , C12N15/62 , C12N15/85 , C12N5/0783
-
公开(公告)号：EP3180011A1
公开(公告)日：2017-06-21
申请号：EP15832624.9
申请日：2015-08-17
Applicant: University Health Network
Inventor： ZHANG, Li , LEE, Jong Bok , CHEN, Branson
CPC classification number: A61K39/0011 , A61K31/7068 , A61K35/17 , A61K2039/5158
Abstract: Methods for the treatment of cancer using double negative (DN) T cells are described. The DNTs may be used for the treatment of chemotherapy-resistant cancers such as recurring or relapsing acute myeloid leukemia (AML). The use of allogenic DNTs, such as those derived from healthy donors, that do not exhibit toxicity towards normal host tissues and the complications associated with graft-versus-host-disease, is also described.
Abstract translation: 描述了使用双阴性（DN）T细胞治疗癌症的方法。 DNT可用于治疗化疗耐药性癌症，如复发或复发性急性髓性白血病（AML）。 也描述了对正常宿主组织没有表现出毒性以及与移植物抗宿主病有关的并发症的同种异体DNT，例如源自健康供体的DNT。
-
公开(公告)号：EP1948788A1
公开(公告)日：2008-07-30
申请号：EP06804734.9
申请日：2006-11-20
Applicant: University Health Network
Inventor： ZHANG, Li , HAN, Mei , DOKOUHAKI, Pouneh
CPC classification number: A61K35/17 , C12N5/0636 , C12N2501/23 , C12N2501/2302 , C12N2501/2304 , C12N2501/515
Abstract: A method of expanding double negative T cells in culture is described. The method comprises (a) providing a starting sample comprising DN T cells or precursors thereof; (b) substantially depleting CD8+ and CD4+ T cells from the starting sample; (c) culturing the sample from step (b) with an immobilized T cell mitogen in a culture medium comprising an agent that can stimulate DN T cell growth; (d) washing the cells obtained in step (c) and resuspending in a culture medium comprising the agent without the T cell mitogen; and (e) washing the cells obtained in step (d) and resuspending in a culture medium comprising the agent and a soluble T cell mitogen. The DN T cells obtained by the method are useful in a variety of applications including the treatment of cancer, infectious diseases, graft versus host disease and autoimmune disease.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.033 seconds)
